To evaluate the persistence of the antihypertensive effect of perindopril 4 mg þ indapamide 1.25 mg once daily for up to 72 h using the 'missed-dose' technique. Hypertensive patients were initially treated with perindopril 2 mg þ indapamide 0.625 mg once daily. After 4 weeks, the 135 of 216 patients who still had a diastolic BPX85 mm Hg went on to receive perindopril 4 mg þ indapamide 1.25 mg daily for a further 8 weeks. During either week 9 or 11, placebo was substituted for perindopril 4 mg þ indapamide 1.25 mg on either one or two consecutive days to simulate BP changes, which might occur after one or two missed doses. A 24-h ambulatory BP recording was performed at baseline, after 9 or 11 weeks of perindopril þ indapamide therapy and during the simulated missed doses, 24-48 and 48-72 h after the administration of perindopril 4 mg þ indapamide 1.25 mg. Significant (Po0.001) reductions in mean (7s.d.) 24-h ambulatory BP (mm Hg) during the first 24 h after perindopril 4 mg þ indapamide 1.25 mg therapy versus baseline were noted for patients later randomized to the one missed dose (À15.9710.5/ À9.477.6) or two missed dose (À17.478.7/À10.375.1) sub-groups. A significant reduction in BP (Po0.001 versus baseline) was still present on the days when placebo was substituted for perindopril 4 mg þ indapamide 1.25 mg with decreases in mean 24-h ambulatory BP from 24 to 48 h and 48 to 72 h after dosing being À11.9710.1/À6.976.2 and À10.679.9/À5.875.7, respectively. Use of the 'misseddose' technique has demonstrated a prolonged antihypertensive effect for perindopril 4 mg þ indapamide 1.25 mg for up to 72 h, supporting the use of this combination as therapy for hypertension.
Introduction
Despite the availability of effective therapy, control of hypertension on a worldwide basis is still rather disappointing. Depending upon definitions for 'hypertension', goal blood pressure (BP) is being achieved in only 10-30% of patients. 1 No doubt there are many factors contributing to the inadequate control of hypertension including poor patient compliance, drug costs and perceived adverse effects related to specific therapies. An important physician-related factor is a tendency to prescribe insufficient doses or too few drugs. This practice occurs despite strong evidence that most patients require multiple drug therapy to achieve goal BP. For example, patients enrolled in ALLHAT 2 received an average of 2.0 drugs whereas hypertensive patients with diabetes in studies such as INSIGHT, LIFE and HOT took three or more agents and still had difficulty achieving goal BP. [3] [4] [5] Whereas in the past, most hypertension guidelines focussed primarily on which drug was the best single agent, physicians are now encouraged to add a second (or third) drug rather than having monotherapy as an implicit goal in itself. [6] [7] [8] One way to encourage combination therapy and achieve goal BP in a higher percentage of patients is to have multiple agents available in one tablet. Combination therapy makes sense if there is a sound basis for including specific drugs in a single tablet. For example, the combination of perindopril and indapamide would seem logical from a physiological perspective in that the diuretic tends to activate the renin-angiotensin system and lower serum potassium whereas perindopril has the opposite effect.
The combination of perindopril 4 mg þ indapamide 1.25 mg is now available as a single tablet for the treatment of hypertension. Dose-response studies have shown these doses to be optimum in terms of efficacy and safety. 9, 10 If this combination is to be used in clinical practice it would be of interest to know the extent to which it lowers BP over a standard 24-h dosing interval. As adherence to longterm antihypertensive therapy is variable, it would also be useful to know the duration of action of this combination over longer periods in order to appreciate the consequences of missing one or two doses on BP control in non-compliant patients.
In the present study, the duration of action of the combination of perindopril 4 mg þ indapamide 1.25 mg has been examined using the simulated 'missed-dose technique' in which placebo was substituted for either 1 or 2 days and persistence of antihypertensive effect followed for up to 72 h using ambulatory blood pressure monitoring.
Methods

Patient population
Male and female patients with mild to moderate essential hypertension were recruited in 14 Canadian centres. Eligible patients were 18-80 years of age, previously untreated or off antihypertensive therapy for at least 4 weeks during which placebo was given, females who were post-menopausal (natural or surgical) and willing to provide written informed consent to participate. To be eligible, at the end of the 4-week placebo run-in period patients were required to have a sitting diastolic BP between 90 and 110 mm Hg and a mean sitting systolic BPo180 mm Hg in addition to having a mean 24-h ambulatory BPX135/85 mm Hg.
Major exclusion criteria were: presence of a secondary cause of hypertension, target organ damage such as prior myocardial infarction, stroke, serum creatinine 4160 mM/l, diabetes mellitus requiring medication, liver enzymes less than three upper limit of normal, previous intolerance of ACEinhibitors, thiazide diuretics or sulfonamides, suspected poor cooperation or compliance with the protocol or use of other drugs known to affect BP.
The study was approved by an independent Ethics Review Board and all subjects provided written, informed consent.
Study design
This multicentre study utilized a randomized, double-blind, parallel-group design to assess the persistence of the antihypertensive effect of combined perindopril 4 mg þ indapamide 1.25 mg therapy for periods up to 72 h after tablet administration. All patients who satisfied the eligibility criteria were entered into a 4-week run-in period when open-label perindopril 2 mg þ indapamide 0.625 mg was given once daily as a single combination tablet. Patients who did not achieve goal BP (office diastolic BPo85 mm Hg) at week 4 had the dose increased to perindopril 4 mg þ indapamide 1.25 mg daily and continued into the next phase of the study. Patients with an office diastolic BPo85 mm Hg at week 4 were allocated to a separate study which examined the persistence of the antihypertensive effect of the low-dose combination of perindopril 2 mg þ indapamide 0.625 mg daily. 11, 12 At week 8, patients receiving perindopril 4 mg þ indapamide 1.25 mg with a BPX160/100 mm Hg were excluded on the basis of poor control of hypertension. The remaining patients were entered into the randomized, double-blind, placebo-controlled second phase of the study.
In phase 2 (weeks 8-12), patients were randomly allocated to one of four groups with groups 1 and 2 having a placebo tablet substituted for active (perindopril þ indapamide) therapy on one day in either week 9 or week 11. Groups 3 and 4 had placebo tablets substituted on two consecutive days either during weeks 9 or 11. Those patients randomly allocated to receiving placebo in week 9 received active (perindopril þ indapamide) therapy during week 11 whereas patients receiving placebo in week 11 were on active therapy in week 9. Thus, patients who received placebo for 1 day went 48 h until the next dose was taken and those receiving placebo for 2 days went 72 h until the next dose. The placebo tablets and active (perindopril þ indapamide) therapies were identical in appearance and otherwise indistinguishable. Study medication was to be taken in the morning and tablets were administered by study personnel at each visit including days when the ambulatory BP recorder was attached.
An ambulatory BP recording was performed for a minimum 24 h at baseline (week 0) and during weeks 9 and 11 when patients were receiving either perindopril 4 mg þ indapamide 1.25 mg daily or a placebo. On the placebo day, the ambulatory BP recording was performed either 24-48 h after the last dose of perindopril þ indapamide (simulated one missed dose group) or 48-72 h after the last dose of perindopril þ indapamide (simulated two missed doses group).
Procedures
Office BP was measured three times at 1-min intervals using a standard mercury sphygmomanometer following an initial 5-min period of resting in a quiet room. Readings were taken in the morning, before the next dose of medication. Current guidelines of the Canadian Hypertension Society 8 for manual measurement of BP were followed. The mean sitting BP was obtained from the second and third readings with the first reading being discarded.
The 24-h ambulatory BP recordings were obtained using a SpaceLabs model 90207 (Spacelabs Medical, Issaquah, WA, USA) device with readings being taken at 15 min intervals during awake hours (0600-2200 h) and every 30 min during sleep (2200-0600 h). A 24-h ambulatory BP recording was considered to be valid and included in the efficacy analysis if at least 80% of readings over the entire 24 h were present without missing more than 1 h of readings during the day or two consecutive hours of readings at night. Patients took their study medication under supervision at the time of initiation of the 24-h ambulatory BP recording.
Medications required for the treatment of other pre-existing conditions at study entry were continued if these did not interfere with BP or end point evaluation. All concomitant medications were recorded during the study and any changes noted.
Office BP and safety evaluations were made at each office visit. BP and heart rate were recorded, changes in physical examination or laboratory parameters were noted and any adverse events documented. Compliance was assessed by tablet counts of bottles returned at each visit. Patients who had compliance rates o80% or 4110% at week 8 were considered non-compliant to therapy and were excluded from the double-blind, missed-dose phase of the study.
A patient could be removed from the study at any time if any of the following occurred: adverse event or abnormal laboratory value which precluded further participation, treatment failure, serious intercurrent illness, use of unauthorized therapy affecting the conduct of the study or non-compliance with study medication or the protocol.
Statistical analysis
The primary outcome measure was the change in 24-h ambulatory BP from baseline after 9 or 11 weeks of combination therapy with perindopril 4 mg þ indapamide 1.25 mg daily compared to values 24-48 h (one simulated missed dose) or 48-72 h (two simulated missed doses) after tablet administration. The effect of simulated non-compliance for 1 or 2 days was also evaluated by comparing changes in daytime (0600-1800 h), evening (1800-0000 h) and night time (0000-0600 h) ambulatory BP versus baseline on perindopril þ indapamide versus 24-48 or 48-72 h after dosing.
Descriptive variables are stated as mean7s.d. Analysis of variance for repeated measures was performed to assess differences in both primary and secondary endpoints for one or two missed doses. The visit Â pattern interaction was assessed to exclude an order effect in the randomization process. All tests were two-sided and were performed at a significance level of a ¼ 0.05.
Results
A total of 398 patients were screened for the study. Of these, 224 satisfied the eligibility criteria and were enrolled into the active treatment phase. A total of 223 patients took study medication. Of these, 209 were maintained at week 8 in a specific treatment group while 14 were discontinued from the study before randomization (four withdrew consent, three were deemed to be ineligible, three used unauthorized concomitant medications, three had a lack of efficacy data and one experienced minor adverse event). Of the remaining 209 patients, 79 patients achieved goal BP on the combination of perindopril 2 mg þ indapamide 0.625 mg daily and remained on this dose. The 130 patients with an office diastolic BPX85 mm Hg at week 4 who went on to receive combination therapy with perindopril 4 mg þ indapamide 1.25 mg once daily for the following 8 weeks constituted the patients entering the randomization phase of the study.
This subgroup of 130 patients had a mean age of 55.579.2 years and included 79 male patients and 51 female patients. The duration of hypertension was 4.6 þ 5.3 years and 96% of patients had been receiving antihypertensive therapy before the 4-week wash-out period. Mean office BP at baseline (week 0) was 154.5 þ 11.5/96.175.2 mm Hg.
Patients successfully completing the randomization period (weeks 8-12) included 59 of 65 patients randomized to one simulated missed-dose (24-48 h) and 62 of 65 patients randomized to two simulated missed-doses (48-72 h). Nine patients were excluded from the efficacy analysis for the following reasons: three used unauthorized concomitant medications, three had a lack of efficacy data with ambulatory BP recordings not available at week 9 or 11, two were deemed to be ineligible and one withdrew consent.
Tablet counts confirmed that more than 99% of the patient population was compliant to treatment during the study.
Outcome measures
The mean 24 h ambulatory BP was significantly (Po0.001) reduced after 9 or 11 weeks of treatment with perindopril 4 mg þ indapamide 1.25 mg daily in both the simulated one and two missed dose subgroups (Table 1) . Hourly changes in mean systolic and diastolic BP for 0-24, 24-48 and 48-72 h after dosing with perindopril 4 mg þ indapamide 1.25 mg are shown in Figure 1 . Significant (Po0.001) reductions in ambulatory BP after 9-11 week compared with baseline were also seen in each period of the day including daytime, evening and night time (Table 1) .
Mean 24-h ambulatory BP values after one missed dose or after two consecutive missed doses remained significantly (Po0.001) decreased from baseline ( Table 1 ). The fall in mean 24-h ambulatory BP on perindopril 4 mg þ indapamide 1.25 mg daily after 9 or 11 weeks of treatment was À15.9710.5/ À9.477.6 and À17.478.7/À10.375.1 mm Hg, for the one and two missed dose sub-groups, respectively (Figure 2 ). Comparable reductions in ambulatory BP versus baseline were À11.9710.1/À6.976.2 for one missed dose (24-48 h following tablet administration) and À10.679.9/À5.875.7 mm Hg after two consecutive missed doses (48-72 h following tablet administration). Changes in mean 24-h ambulatory BP were greater between 0-24 versus 24-48 h than for 24-48 versus 48-72 h. Mean ambulatory BP values for daytime, evening and night time were significantly decreased from baseline (Po0.001) for both the one and the two missed dose sub-groups ( Table 1) .
The residual reduction in mean 24 h ambulatory BP following one missed dose (24-48 h) was 75/75% for systolic/diastolic compared with the fall in ambulatory BP on perindopril 4 mg þ indapamide 1.25 mg. Similarly, 61/56% of the fall in ambulatory BP on perindopril 4 mg þ indapamide 1.25 mg was still present after two missed doses (48-72 h).
Office BP readings showed similar reductions compared with baseline values. At the end of the study (week 12), mean office BP was 137.7711.9/ 86.977.0 mm Hg compared with 154.5711.5/ 96.175.2 mm Hg at baseline (week 0). Heart rate at week 12 (73.0710.3 beats/min) was unchanged from baseline value (72.7710.1).
Adverse effects
No deaths were reported during the study. One patient experienced a suspected arterial embolus to the leg during the placebo washout period before the baseline (week 0) visit. No abnormal physical findings were noted on perindopril þ indapamide therapy. Mean (7s.d.) serum uric acid which increased by 23.9750.4 mcg/l to 368.7788.4 mcg/l at week 12 compared with baseline whereas serum potassium was decreased by 0.270.6 mM at week 12 with the mean value being 4.370.5 mM. Two patients exhibited hypokalemia (serum potassium o3.5 mmol/l).
Discussion
In the present study, a simulated missed-dose technique has demonstrated a prolonged antihypertensive effect of perindopril 4 mg þ indapamide 1.25 mg for at least 72 h following the last dose taken. The use of this approach with a double-blind, randomized, placebo-controlled study design would appear to provide the best evidence of an agent's duration of action.
The results indicate that about 75% of the reduction in BP on perindopril 4 mg þ indapamide 1.25 mg over the first 24 h is still present on the following day when a placebo is substituted for active therapy. The results of simulated two misseddoses of non-compliance showed more than half of the antihypertensive effect persisting for at least 72 h after dosing with the fixed combination of perindopril 4 mg þ indapamide 1.25 mg.
In real life, patients do not exhibit 100% adherence to long-term drug therapy with missed doses being a relatively frequent occurrence. Indeed, 80% compliance is generally accepted as being sufficient to achieve meaningful reductions in BP over prolonged periods. 13 Thus, it is useful to know if a specific antihypertensive treatment maintains good BP control over a more extended period than a single dosing interval. As seen in the present study, the simulated missed-dose technique can provide information on the BP lowering effect of antihypertensive therapy for periods up to 72 h.
Several other methods are available for evaluating the time course of the BP lowering effect of an antihypertensive drug. 13 Examples of previous studies using these methods are listed in Table 2 . Office BP can be used to demonstrate similar reductions in BP at trough, 24 h after dosing, with either oncedaily therapy or with the same dose given as a twicedaily regimen.
14 Periodic BP readings over 8-12 h and at 24 h under controlled conditions in a research setting have been used to estimate the trough-topeak ratio of different antihypertensive agents. 15 More frequently, others have used 24-h ambulatory BP recordings to determine trough-to-peak ratio of specific agents. 16 In both instances, the absence of standardized methodology has made the interpretation of these findings difficult and has limited comparability among different studies with different agents. 13 Other methods employing 24-h ambulatory BP monitoring include an examination of the changes in BP over 24 h after dosing following 4-8 weeks of active therapy compared with baseline. Graphic display of the changes in blood pressure over 24 h will usually demonstrate the effects of the antihypertensive drug including any loss in BP control toward the end of the dosing interval. over time. 18 Even among individuals, the 24-h ambulatory BP shows greater reproducibility than does the office BP, which tends to exhibit a regression to the mean phenomenon. 18, 19 This aspect of ambulatory BP monitoring allows utilization of a before-after study design in evaluating duration of action during the first 24 h after dosing.
In order to simplify the analysis of hourly BP data and increase statistical power, we have used mean daytime, evening and night time values obtained with 24-h ambulatory blood pressure monitoring during chronic antihypertensive therapy and compared mean changes in BP versus the same periods on placebo at baseline. For example, we have previously demonstrated a more prolonged duration of action for a dihydropyridine calcium channel blocker (nifedipine-GITS) compared with a similar agent (felodipine-ER) and the lack of 24-h antihypertensive efficacy of an ACE-inhibitor (enalapril) given once daily as a positive control. 20 Other studies have utilized the missed-dose technique to demonstrate the persistence of effect of specific antihypertensive drugs given as monotherapy. In one study using two simulated misseddoses, Leenen et al. 21 showed that amlodipine 5-10 mg once daily, reduced BP for up to 72 h after dosing. Between 48 and 72 h after dosing, more than 75% of the antihypertensive effect of amlodipine was still present. Similar findings were noted by Smilde et al. 22 who showed a persistent decrease in ambulatory BP up to 72 h after taking amlodipine versus a loss in BP control with shorter-acting felodipine-ER. Unlike the study of Leenen et al., 21 this study did not utilize a randomized, doubleblind design and placebo was not given on the simulated missed-dose days. In another study comparing the duration of action of trandolapril versus enalapril, 16 substitution of a placebo for active therapy showed most (50-65%) of the antihypertensive effects of trandolapril present 24-48 h after dosing compared with a loss of BP control with once daily enalapril therapy. Similar findings were observed in a study by Leenen and Tan 23 in which placebo was substituted on one day for perindopril 4 or 8 mg and changes in BP 24-48 h after dosing compared with those noted during therapy 0-24 h after tablet administration. More than 75% of the antihypertensive effect persisted on the simulated missed-dose day. The authors were unable to find any other missed-dose study for a diuretic and ACEinhibitor combination. The antihypertensive profiles of hydrochlorothiazide 24 and bendrofluazide 25 have been examined using 24-h ambulatory BP monitoring and both diuretics appear to reduce BP consistently over a 24-h dosing interval. In the present study, both indapamide and perindoprilat, the active metabolite of perindopril, have a long terminal elimination half-life when administered either as single drug or in combination. 26, 27 Perindopril also produces about 70% inhibition of the angiotensin converting enzyme 24 h after oral ingestion. 28 Until the present study, there have not been no data on the time course of the blood pressure lowering effect of the perindopril 4 mg þ indapamide 1.25 mg combination over periods of 24 h or more.
Does the loss of BP control during the 24-72 h after dosing have any clinical consequences? The available literature would suggest that it does. In one study, 21 there was better BP control in non-compliant patients who took o80% of a longer-acting, once daily agent (amlodipine) compared with patients exhibiting similar degrees of non-compliance but on a twice-daily regimen of a shorter-acting formulation of diltiazem. These findings indicate that loss of BP control with non-compliance can be minimized if longer-acting drugs are prescribed.
In summary, use of the simulated missed-dose technique over periods of up to 72 h provides the best measure of the persistence of antihypertensive efficacy. The fixed-dose combination perindopril 4 mg þ indapamide 1.25 mg has a prolonged antihypertensive effect for at least 72 h and should improve the likelihood of a patient achieving goal Loss of antihypertensive effect with enalapril during night Missed-dose study using placebo substitution for active drug Amlodipine versus diltiazem after 2 days of placebo therapy 21 Greater persistence of BP fall with amlodipine Perindopril and indapamide in hypertensionBP and consistent control of hypertension over prolonged periods, even on days when scheduled doses are missed.
What's known about this topic K Compliance with antihypertensive therapy is often variable with patients forgetting to take their medication on a daily basis. K Drugs which maintain a reduction in BP for 48 h or longer may still provide full therapeutic coverage even if doses are missed. K Most patients require two or more drugs such as an ACEinhibitor and diuretic to achieve goal BP but little is known about the duration of the antihypertensive effect of these combinations.
What this study adds K This study utilized a novel, missed-dose technique to demonstrate a prolonged reduction in BP following chronic administration of a combination of perindopril and indapamide in patients with mild to moderate essential hypertension. K Patients receiving this type of combination therapy may still benefit from a reduction in BP for up to 72 h after taking the last dose thereby avoiding loss of BP control when doses are missed.
Abbreviations: BP, blood pressure; ACE, angiotensin converting enzyme.
